JP2003514011A - チアゾリジンジオン−塩酸メトホルミンを含む医薬組成物 - Google Patents

チアゾリジンジオン−塩酸メトホルミンを含む医薬組成物

Info

Publication number
JP2003514011A
JP2003514011A JP2001537933A JP2001537933A JP2003514011A JP 2003514011 A JP2003514011 A JP 2003514011A JP 2001537933 A JP2001537933 A JP 2001537933A JP 2001537933 A JP2001537933 A JP 2001537933A JP 2003514011 A JP2003514011 A JP 2003514011A
Authority
JP
Japan
Prior art keywords
metformin hydrochloride
thiazolidinedione
composition
composition according
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001537933A
Other languages
English (en)
Japanese (ja)
Inventor
カレン・ルイス
ニコラ・ジェーン・リロット
ドナルド・コリン・マッケンジー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9927121.5A external-priority patent/GB9927121D0/en
Priority claimed from GB0013238A external-priority patent/GB0013238D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of JP2003514011A publication Critical patent/JP2003514011A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2001537933A 1999-11-16 2000-11-16 チアゾリジンジオン−塩酸メトホルミンを含む医薬組成物 Pending JP2003514011A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9927121.5A GB9927121D0 (en) 1999-11-16 1999-11-16 Novel composition and use
GB9927121.5 1999-11-16
GB0013238.1 2000-05-31
GB0013238A GB0013238D0 (en) 2000-05-31 2000-05-31 Novel composition and use
PCT/GB2000/004363 WO2001035940A2 (fr) 1999-11-16 2000-11-16 Nouvelle composition et utilisation

Publications (1)

Publication Number Publication Date
JP2003514011A true JP2003514011A (ja) 2003-04-15

Family

ID=26244395

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001537933A Pending JP2003514011A (ja) 1999-11-16 2000-11-16 チアゾリジンジオン−塩酸メトホルミンを含む医薬組成物

Country Status (4)

Country Link
EP (1) EP1231917A2 (fr)
JP (1) JP2003514011A (fr)
AU (1) AU1403501A (fr)
WO (1) WO2001035940A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005099760A1 (fr) * 2004-04-14 2005-10-27 Takeda Pharmaceutical Company Limited Préparation pharmaceutique solide
JP2007505903A (ja) * 2003-09-19 2007-03-15 アンドルックス ラボズ リミテッド ライアビリティ カンパニー ビグアニドおよびチアゾリジンジオン誘導体を含む新規の医薬製剤
JP2008534589A (ja) * 2005-03-30 2008-08-28 ワトソン ファーマスーティカルズ インコーポレーテッド ビグアニドおよびチアゾリジンジオン誘導体を含有する新規な医薬品製剤

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR030920A1 (es) 1999-11-16 2003-09-03 Smithkline Beecham Plc Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
ATE367151T1 (de) * 2000-05-01 2007-08-15 Aeropharm Technology Llc Kernformulierung
WO2003005991A1 (fr) * 2001-07-10 2003-01-23 Aeropharm Technology Incorporated Formulation de noyau
CA2453782A1 (fr) * 2001-07-10 2003-01-23 Kos Life Sciences, Inc. Formulation de noyau comprenant de la troglitazone et un biguanide
EP1515701B1 (fr) * 2002-06-17 2014-09-17 Inventia Healthcare Private Limited Procédé de fabrication de comprimés multicouches comprenant de la thiazolidinedione et du biguanide
WO2004006921A1 (fr) * 2002-07-11 2004-01-22 Takeda Pharmaceutical Company Limited Procede de production d'une preparation recouverte
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
AU2003272504A1 (en) * 2002-09-20 2004-04-08 Andrx Labs Llc Multistage formulation containing a biguanide and thiazolidindione derivatives
UA80991C2 (en) * 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
JP4567340B2 (ja) * 2003-01-29 2010-10-20 武田薬品工業株式会社 被覆製剤の製造方法
MXPA05007883A (es) * 2003-01-29 2005-09-21 Takeda Pharmaceutical Proceso para producir una preparacion recubierta.
ZA200506397B (en) * 2003-01-29 2006-11-29 Takeda Pharmaceutical Process for producing coated preparation
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
TR201202048T2 (tr) * 2009-05-26 2012-04-24 Abdi̇ İbrahi̇m İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇@ Pioglitazon çözeltisi ile kaplanmış metformin.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE355840T1 (de) * 1997-06-18 2007-03-15 Smithkline Beecham Plc Behandlung der diabetes mit thiazolidindione und metformin
GB9715295D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
KR100620935B1 (ko) * 1998-03-19 2006-09-13 브리스톨-마이어스스퀴브컴파니 용해도가 높은 약물에 대한 2상 서방성 전달 시스템과 방법

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007505903A (ja) * 2003-09-19 2007-03-15 アンドルックス ラボズ リミテッド ライアビリティ カンパニー ビグアニドおよびチアゾリジンジオン誘導体を含む新規の医薬製剤
JP4718465B2 (ja) * 2003-09-19 2011-07-06 アンドルックス ラボズ リミテッド ライアビリティ カンパニー ビグアニドおよびチアゾリジンジオン誘導体を含む新規の医薬製剤
JP2011148819A (ja) * 2003-09-19 2011-08-04 Andrx Labs Llc ビグアニドおよびチアゾリジンジオン誘導体を含む新規の医薬製剤
WO2005099760A1 (fr) * 2004-04-14 2005-10-27 Takeda Pharmaceutical Company Limited Préparation pharmaceutique solide
JPWO2005099760A1 (ja) * 2004-04-14 2008-03-06 武田薬品工業株式会社 固形製剤
JP4739189B2 (ja) * 2004-04-14 2011-08-03 武田薬品工業株式会社 固形製剤
JP2008534589A (ja) * 2005-03-30 2008-08-28 ワトソン ファーマスーティカルズ インコーポレーテッド ビグアニドおよびチアゾリジンジオン誘導体を含有する新規な医薬品製剤
JP2013209426A (ja) * 2005-03-30 2013-10-10 Actavis Inc ビグアニドおよびチアゾリジンジオン誘導体を含有する新規な医薬品製剤

Also Published As

Publication number Publication date
WO2001035940A2 (fr) 2001-05-25
AU1403501A (en) 2001-05-30
WO2001035940A3 (fr) 2002-03-21
EP1231917A2 (fr) 2002-08-21

Similar Documents

Publication Publication Date Title
JP4865975B2 (ja) 新規組成物および使用
AU768994B2 (en) Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
JP2003514011A (ja) チアゾリジンジオン−塩酸メトホルミンを含む医薬組成物
US20050136111A1 (en) Novel composition and use
KR100732599B1 (ko) 조절 방출형 인슐린 감작제용 제약 조성물
JP2001510158A (ja) チアゾリジンジオンおよびスルホニル尿素を用いる糖尿病の治療
AU2757202A (en) Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
AU2008203540A1 (en) Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
AU2005200704A1 (en) Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
AU2004233487A1 (en) Pharmaceutical composition for modified release insulin sensitiser
AU2008202896A1 (en) Pharmaceutical composition for modified release insulin sensitiser
ZA200203865B (en) Novel composition and use.
AU2757302A (en) Pharmaceutical composition for modified release insulin sensitiser
ZA200103843B (en) Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent.
ZA200103842B (en) Pharmaceutical composition for modified release insulin sensitiser.